Combination monoamine oxidase inhibitor and β-blocker treatment of migraine, with anxiety and depression
This paper presents the results of a study comparing the effectiveness of a β-adrenergic blocking agent, atenolol, a monoamine oxidase inhibitor (MAO-I), phenelzine, and the combination in treatment of 61 adults with migraine headache. The goals of the study are (1) to investigate the safety of conc...
Gespeichert in:
| Veröffentlicht in: | Biological psychiatry (1969) 1995-11, Vol.38 (9), p.603-610 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 610 |
|---|---|
| container_issue | 9 |
| container_start_page | 603 |
| container_title | Biological psychiatry (1969) |
| container_volume | 38 |
| creator | Merikangas, Kathleen R. Merikangas, James R. |
| description | This paper presents the results of a study comparing the effectiveness of a
β-adrenergic blocking agent, atenolol, a monoamine oxidase inhibitor (MAO-I), phenelzine, and the combination in treatment of 61 adults with migraine headache. The goals of the study are (1) to investigate the safety of concomitant treatment of migraine with
β-blockers and phenelzine, (2) to assess whether orthostatic hypertension and other side effects would be relieved, and (3) to compare the results of this open trial of phenelzine to those of a previous study using similar methods. Phenelzine was associated with a large decrease in the frequency and severity of migraine attacks. Anxiety and depression were also reduced by phenelzine both alone, and in combination with a
β-blocker. The results show that the combination of MAO-I's and
β-blockers can be administered safely, and can lead to the reduction in the side effects with either drug alone. |
| doi_str_mv | 10.1016/0006-3223(95)00077-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77801166</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0006322395000771</els_id><sourcerecordid>77801166</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-7dc93d218d1ca79580297a652bbb4a182f9fcfa3252acb959c9ab96ca622304f3</originalsourceid><addsrcrecordid>eNp9kNFqFDEUhoModVt9A4W5EKngaJKZSSY3gixaC4Xe6HU4Sc7Y6EyyJlnbvpYP4jOZ7S576dUhnO__OfkIecHoO0aZeE8pFW3HeXeuhjf1IWXLHpEVG2XX8p7yx2R1RJ6S05x_7CDO2Qk5GQfZCcFXxK_jYnyA4mNolhgiLD5gE--8g4yNDzfe-BJTA8E1f_-0Zo72J6amJISyYChNnJrFf09QY2-bW19uKnrnsdw_RBxuEuZc25-RJxPMGZ8f5hn59vnT1_WX9ur64nL98aq1fcdLK51VneNsdMyCVMNIuZIgBm6M6YGNfFKTnaDjAwdr1KCsAqOEBVG_SfupOyOv972bFH9tMRe9-GxxniFg3GYt5UgZE6KC_R60KeaccNKb5BdI95pRvTOsd_r0Tp9Wg34wrFmNvTz0b82C7hg6KK37V4c9ZAvzlCBYn48YV1RIMVTswx7D6uK3x6Sz9RgsOp_QFu2i__8d_wDu7ZkY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77801166</pqid></control><display><type>article</type><title>Combination monoamine oxidase inhibitor and β-blocker treatment of migraine, with anxiety and depression</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Merikangas, Kathleen R. ; Merikangas, James R.</creator><creatorcontrib>Merikangas, Kathleen R. ; Merikangas, James R.</creatorcontrib><description>This paper presents the results of a study comparing the effectiveness of a
β-adrenergic blocking agent, atenolol, a monoamine oxidase inhibitor (MAO-I), phenelzine, and the combination in treatment of 61 adults with migraine headache. The goals of the study are (1) to investigate the safety of concomitant treatment of migraine with
β-blockers and phenelzine, (2) to assess whether orthostatic hypertension and other side effects would be relieved, and (3) to compare the results of this open trial of phenelzine to those of a previous study using similar methods. Phenelzine was associated with a large decrease in the frequency and severity of migraine attacks. Anxiety and depression were also reduced by phenelzine both alone, and in combination with a
β-blocker. The results show that the combination of MAO-I's and
β-blockers can be administered safely, and can lead to the reduction in the side effects with either drug alone.</description><identifier>ISSN: 0006-3223</identifier><identifier>EISSN: 1873-2402</identifier><identifier>DOI: 10.1016/0006-3223(95)00077-1</identifier><identifier>PMID: 8573662</identifier><identifier>CODEN: BIPCBF</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adrenergic beta-Antagonists - pharmacology ; Adrenergic beta-Antagonists - therapeutic use ; Adult ; Anxiety - complications ; Anxiety - diagnosis ; Anxiety - drug therapy ; atenolol ; Atenolol - pharmacology ; Atenolol - therapeutic use ; Biological and medical sciences ; Blood Pressure - drug effects ; Depressive Disorder - complications ; Depressive Disorder - diagnosis ; Depressive Disorder - drug therapy ; Disability Evaluation ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Humans ; Male ; Medical sciences ; migraine ; Migraine Disorders - complications ; Migraine Disorders - diagnosis ; Migraine Disorders - drug therapy ; monoamine oxidase inhibitor ; Monoamine Oxidase Inhibitors - pharmacology ; Monoamine Oxidase Inhibitors - therapeutic use ; Neuropharmacology ; Pharmacology. Drug treatments ; phenelzine ; Phenelzine - pharmacology ; Phenelzine - therapeutic use ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Treatment Outcome ; β-Adrenergic blocking agent</subject><ispartof>Biological psychiatry (1969), 1995-11, Vol.38 (9), p.603-610</ispartof><rights>1995 Society of Biological Psychiatry</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-7dc93d218d1ca79580297a652bbb4a182f9fcfa3252acb959c9ab96ca622304f3</citedby><cites>FETCH-LOGICAL-c432t-7dc93d218d1ca79580297a652bbb4a182f9fcfa3252acb959c9ab96ca622304f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0006-3223(95)00077-1$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2906765$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8573662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Merikangas, Kathleen R.</creatorcontrib><creatorcontrib>Merikangas, James R.</creatorcontrib><title>Combination monoamine oxidase inhibitor and β-blocker treatment of migraine, with anxiety and depression</title><title>Biological psychiatry (1969)</title><addtitle>Biol Psychiatry</addtitle><description>This paper presents the results of a study comparing the effectiveness of a
β-adrenergic blocking agent, atenolol, a monoamine oxidase inhibitor (MAO-I), phenelzine, and the combination in treatment of 61 adults with migraine headache. The goals of the study are (1) to investigate the safety of concomitant treatment of migraine with
β-blockers and phenelzine, (2) to assess whether orthostatic hypertension and other side effects would be relieved, and (3) to compare the results of this open trial of phenelzine to those of a previous study using similar methods. Phenelzine was associated with a large decrease in the frequency and severity of migraine attacks. Anxiety and depression were also reduced by phenelzine both alone, and in combination with a
β-blocker. The results show that the combination of MAO-I's and
β-blockers can be administered safely, and can lead to the reduction in the side effects with either drug alone.</description><subject>Adrenergic beta-Antagonists - pharmacology</subject><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Adult</subject><subject>Anxiety - complications</subject><subject>Anxiety - diagnosis</subject><subject>Anxiety - drug therapy</subject><subject>atenolol</subject><subject>Atenolol - pharmacology</subject><subject>Atenolol - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Depressive Disorder - complications</subject><subject>Depressive Disorder - diagnosis</subject><subject>Depressive Disorder - drug therapy</subject><subject>Disability Evaluation</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>migraine</subject><subject>Migraine Disorders - complications</subject><subject>Migraine Disorders - diagnosis</subject><subject>Migraine Disorders - drug therapy</subject><subject>monoamine oxidase inhibitor</subject><subject>Monoamine Oxidase Inhibitors - pharmacology</subject><subject>Monoamine Oxidase Inhibitors - therapeutic use</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>phenelzine</subject><subject>Phenelzine - pharmacology</subject><subject>Phenelzine - therapeutic use</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Treatment Outcome</subject><subject>β-Adrenergic blocking agent</subject><issn>0006-3223</issn><issn>1873-2402</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kNFqFDEUhoModVt9A4W5EKngaJKZSSY3gixaC4Xe6HU4Sc7Y6EyyJlnbvpYP4jOZ7S576dUhnO__OfkIecHoO0aZeE8pFW3HeXeuhjf1IWXLHpEVG2XX8p7yx2R1RJ6S05x_7CDO2Qk5GQfZCcFXxK_jYnyA4mNolhgiLD5gE--8g4yNDzfe-BJTA8E1f_-0Zo72J6amJISyYChNnJrFf09QY2-bW19uKnrnsdw_RBxuEuZc25-RJxPMGZ8f5hn59vnT1_WX9ur64nL98aq1fcdLK51VneNsdMyCVMNIuZIgBm6M6YGNfFKTnaDjAwdr1KCsAqOEBVG_SfupOyOv972bFH9tMRe9-GxxniFg3GYt5UgZE6KC_R60KeaccNKb5BdI95pRvTOsd_r0Tp9Wg34wrFmNvTz0b82C7hg6KK37V4c9ZAvzlCBYn48YV1RIMVTswx7D6uK3x6Sz9RgsOp_QFu2i__8d_wDu7ZkY</recordid><startdate>19951101</startdate><enddate>19951101</enddate><creator>Merikangas, Kathleen R.</creator><creator>Merikangas, James R.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19951101</creationdate><title>Combination monoamine oxidase inhibitor and β-blocker treatment of migraine, with anxiety and depression</title><author>Merikangas, Kathleen R. ; Merikangas, James R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-7dc93d218d1ca79580297a652bbb4a182f9fcfa3252acb959c9ab96ca622304f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adrenergic beta-Antagonists - pharmacology</topic><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Adult</topic><topic>Anxiety - complications</topic><topic>Anxiety - diagnosis</topic><topic>Anxiety - drug therapy</topic><topic>atenolol</topic><topic>Atenolol - pharmacology</topic><topic>Atenolol - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Depressive Disorder - complications</topic><topic>Depressive Disorder - diagnosis</topic><topic>Depressive Disorder - drug therapy</topic><topic>Disability Evaluation</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>migraine</topic><topic>Migraine Disorders - complications</topic><topic>Migraine Disorders - diagnosis</topic><topic>Migraine Disorders - drug therapy</topic><topic>monoamine oxidase inhibitor</topic><topic>Monoamine Oxidase Inhibitors - pharmacology</topic><topic>Monoamine Oxidase Inhibitors - therapeutic use</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>phenelzine</topic><topic>Phenelzine - pharmacology</topic><topic>Phenelzine - therapeutic use</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Treatment Outcome</topic><topic>β-Adrenergic blocking agent</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Merikangas, Kathleen R.</creatorcontrib><creatorcontrib>Merikangas, James R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biological psychiatry (1969)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Merikangas, Kathleen R.</au><au>Merikangas, James R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination monoamine oxidase inhibitor and β-blocker treatment of migraine, with anxiety and depression</atitle><jtitle>Biological psychiatry (1969)</jtitle><addtitle>Biol Psychiatry</addtitle><date>1995-11-01</date><risdate>1995</risdate><volume>38</volume><issue>9</issue><spage>603</spage><epage>610</epage><pages>603-610</pages><issn>0006-3223</issn><eissn>1873-2402</eissn><coden>BIPCBF</coden><abstract>This paper presents the results of a study comparing the effectiveness of a
β-adrenergic blocking agent, atenolol, a monoamine oxidase inhibitor (MAO-I), phenelzine, and the combination in treatment of 61 adults with migraine headache. The goals of the study are (1) to investigate the safety of concomitant treatment of migraine with
β-blockers and phenelzine, (2) to assess whether orthostatic hypertension and other side effects would be relieved, and (3) to compare the results of this open trial of phenelzine to those of a previous study using similar methods. Phenelzine was associated with a large decrease in the frequency and severity of migraine attacks. Anxiety and depression were also reduced by phenelzine both alone, and in combination with a
β-blocker. The results show that the combination of MAO-I's and
β-blockers can be administered safely, and can lead to the reduction in the side effects with either drug alone.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>8573662</pmid><doi>10.1016/0006-3223(95)00077-1</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-3223 |
| ispartof | Biological psychiatry (1969), 1995-11, Vol.38 (9), p.603-610 |
| issn | 0006-3223 1873-2402 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77801166 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adrenergic beta-Antagonists - pharmacology Adrenergic beta-Antagonists - therapeutic use Adult Anxiety - complications Anxiety - diagnosis Anxiety - drug therapy atenolol Atenolol - pharmacology Atenolol - therapeutic use Biological and medical sciences Blood Pressure - drug effects Depressive Disorder - complications Depressive Disorder - diagnosis Depressive Disorder - drug therapy Disability Evaluation Drug Administration Schedule Drug Therapy, Combination Female Humans Male Medical sciences migraine Migraine Disorders - complications Migraine Disorders - diagnosis Migraine Disorders - drug therapy monoamine oxidase inhibitor Monoamine Oxidase Inhibitors - pharmacology Monoamine Oxidase Inhibitors - therapeutic use Neuropharmacology Pharmacology. Drug treatments phenelzine Phenelzine - pharmacology Phenelzine - therapeutic use Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Treatment Outcome β-Adrenergic blocking agent |
| title | Combination monoamine oxidase inhibitor and β-blocker treatment of migraine, with anxiety and depression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T04%3A37%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20monoamine%20oxidase%20inhibitor%20and%20%CE%B2-blocker%20treatment%20of%20migraine,%20with%20anxiety%20and%20depression&rft.jtitle=Biological%20psychiatry%20(1969)&rft.au=Merikangas,%20Kathleen%20R.&rft.date=1995-11-01&rft.volume=38&rft.issue=9&rft.spage=603&rft.epage=610&rft.pages=603-610&rft.issn=0006-3223&rft.eissn=1873-2402&rft.coden=BIPCBF&rft_id=info:doi/10.1016/0006-3223(95)00077-1&rft_dat=%3Cproquest_cross%3E77801166%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77801166&rft_id=info:pmid/8573662&rft_els_id=0006322395000771&rfr_iscdi=true |